Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Leases (2021 - 2025)

Historic Current Leases for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $366000.0.

  • Verrica Pharmaceuticals' Current Leases fell 5673.76% to $366000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $366000.0, marking a year-over-year decrease of 5673.76%. This contributed to the annual value of $352000.0 for FY2024, which is 638.3% down from last year.
  • According to the latest figures from Q3 2025, Verrica Pharmaceuticals' Current Leases is $366000.0, which was down 5673.76% from $328000.0 recorded in Q2 2025.
  • Verrica Pharmaceuticals' Current Leases' 5-year high stood at $846000.0 during Q3 2024, with a 5-year trough of $230000.0 in Q1 2021.
  • In the last 5 years, Verrica Pharmaceuticals' Current Leases had a median value of $309000.0 in 2023 and averaged $367894.7.
  • In the last 5 years, Verrica Pharmaceuticals' Current Leases skyrocketed by 16772.15% in 2024 and then tumbled by 5673.76% in 2025.
  • Verrica Pharmaceuticals' Current Leases (Quarter) stood at $245000.0 in 2021, then increased by 21.22% to $297000.0 in 2022, then rose by 26.6% to $376000.0 in 2023, then dropped by 6.38% to $352000.0 in 2024, then grew by 3.98% to $366000.0 in 2025.
  • Its last three reported values are $366000.0 in Q3 2025, $328000.0 for Q2 2025, and $327000.0 during Q1 2025.